LEADER 04757nam 2201609z- 450 001 9910367736503321 005 20240424230057.0 010 $a3-03928-005-8 035 $a(CKB)4100000010106352 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/45503 035 $a(EXLCZ)994100000010106352 100 $a20202102d2019 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aDrug delivery technology development in Canada /$fspecial issue editors, Kishor M. Wasan, Ildiko Badea 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 215 $a1 electronic resource (352 p.) 311 $a3-03928-004-X 330 $aCanada continues to have a rich history of ground-breaking research in drug delivery within academic institutions, pharmaceutical industry and the biotechnology community. 606 $aDrug Delivery Systems$zCanada 610 $aencapsulation 610 $abiodistribution 610 $apharmaceutics 610 $atargeted therapies 610 $agambogic acid 610 $aGE11 peptide 610 $aformulation and dosage form development 610 $atransient modulation 610 $aROESY NMR spectroscopy 610 $abioaccessibility 610 $apolymeric micelle 610 $apharmacological Inhibitors of HIF-1 and STAT3 610 $ananoparticles 610 $aVitamin D 610 $adrug discovery 610 $aEGFR-targeted therapy 610 $atranslational research 610 $aclinical trials 610 $adoxorubicin 610 $adissolution 610 $adrug development 610 $apermeation enhancers 610 $aCanada 610 $aplant 610 $aprimary central nervous system lymphomas 610 $aphotostabilizers 610 $ahead and neck squamous cell carcinoma 610 $amouse models 610 $adrug delivery systems 610 $amelphalan 610 $ahypoxia-induced chemoresistance 610 $askin 610 $avirus 610 $acircadian clock 610 $achild friendly formulation 610 $aadenanthin 610 $aco-delivery 610 $acanola oil deodorizer distillate 610 $aMetaplex 610 $ainnovation 610 $acontrolled drug delivery 610 $anifedipine 610 $aradiolabeling 610 $aamphotericin B 610 $abiological barriers 610 $ablood-brain barrier (BBB) 610 $abiologicals 610 $alipid nanoparticles 610 $aoral formulation 610 $aphytosterols 610 $amedical devices 610 $achronotherapy 610 $aoral 610 $acationic gemini surfactant 610 $aroute of administration 610 $adrug delivery 610 $aintra-arterial chemotherapy 610 $adeveloping world 610 $asustained delivery 610 $awater miscible solvents 610 $acombination therapy 610 $aantibodies 610 $athroughput 610 $amagnetic fields 610 $aliposomes 610 $amedulloblastoma 610 $adrug-resistant melanoma 610 $arosmarinic acid 610 $atopical formulation 610 $aTNO gastrointestinal model 610 $agastrointestinal simulator 610 $amalignant gliomas 610 $atransdermal drug delivery 610 $aoral delivery 610 $aprecision medicine 610 $a3D spheroid 610 $aflavonoids 610 $astaurosporine 610 $aDOX-Vit D 610 $aloading gradients 610 $abacteriophage 610 $aphospholipid complex 610 $atriggered drug release 610 $aHIF-1 610 $aphage display 610 $apharmacokinetics 610 $aemulsion 610 $aquercetin 610 $acisplatin 610 $aparasitic infections 610 $aremote loading 610 $aHAV6 cadherin peptide 610 $ablood-brain barrier 610 $ainclusion complex 610 $atocopherols 610 $aSTAT3 610 $aultrasound 610 $aliposome 610 $afungal infections 610 $amagnetic resonance imaging (MRI) 610 $aMG63 610 $amodel orange juice 610 $aradiation 610 $acancer 610 $amefloquine 610 $asmall molecules 615 0$aDrug Delivery Systems 676 $a615.1/900971 702 $aBadea$b Ildiko 702 $aWasan$b Kishor M. 906 $aBOOK 912 $a9910367736503321 996 $aDrug Delivery Technology Development in Canada$93026772 997 $aUNINA